GSK's hepatitis B drug, Hibsago receives US FDA approval
GSK plc announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse
This is a short summary. The full story is published by Pharma Biz.
Read full story at Pharma Biz
